Search Hollings Cancer Center Clinical Trials

Protocol:
Disease Site:
select
Phase:
select
Physician:
select
Study Type:
select
Research Type:
select
Agent/Device:
Keywords:
 
ProtocolTitleStatusContact
102150Symptom Burden and Radiotherapy: A Feasibility StudyActive/EnrollingInfo
102138Randomized Controlled Study Comparing AEZS-108 with Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer Open-Label, Randomized, Active-Controlled, Multicenter TrialActive/EnrollingInfo
102122A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Subjects with Recurrent Glioblastoma MultiformeActive/EnrollingInfo
102116A Phase I Dose Escalation Study of LEE011 in Combination with Buparlisib and Letrozole for the Treatment of HR+, HER2-Negative Post-Menopausal Women with Locally Advanced or Metastatic Breast CancerActive/EnrollingInfo
102114A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial CancerActive/EnrollingInfo
102113A Randomized Phase II Study With A Phase I Lead-In To Assess The Antitumor Efficacy Of The MEK Inhibitor Trametinib Alone Or In Combination With GSK2141795, An AKT Inhibitor In Patients With Recurrent Or Persistent Endometrial Cancer.Active/EnrollingInfo
102103Protocol CA209143, A Randomized Phase IIB Open Label Study of Nivolumab or Nivolumab in Combination with Ipilimumab versus Bevacizumab in Adult Subjects with Recurrent Glioblastoma (GBM)Active/EnrollingInfo
102097Tissue Procurement Protocol for the Developmental Therapeutics Clinic, National Cancer Institute (NCI)Active/EnrollingInfo
102095A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined With Trametinib and Dabrafenib or Trametinib in Adult Subjects With Metastatic Cutaneous MelanomaActive/EnrollingInfo
102089Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) with Commercially Supplied Sunitinib in Patients with Previously Untreated Metastatic Renal Cell CarcinomaActive/EnrollingInfo
102084A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid MalignanciesActive/EnrollingInfo
102083Phase II Randomized Trial of Transoral Surgical Resection followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx CancerActive/EnrollingInfo
102081A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination with Topotecan (Hycamtin®) in Patients with Solid TumorsActive/EnrollingInfo
102078Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy Squamous Cell Lung CancerActive/EnrollingInfo
102076A Randomized, Double Blind, Placebo-Controlled, Multicenter Phase II Study To Evaluate Efficacy And Safety Of Roniciclib In Subjects With Extensive-Stage Disease Small Cell Lung Cancer (SCLC) Who Are Receiving Cisplatin + Etoposide Or Carboplatin + Etoposide As First-Line TherapyActive/EnrollingInfo
102072A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid CancerActive/EnrollingInfo
102071A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer.Active/EnrollingInfo
102066A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study).Active/EnrollingInfo
102065Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib(GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory AdvancedBiliary Cancer.Active/EnrollingInfo
102063A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid LeukemiaActive/EnrollingInfo
102061A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (>/= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL) Active/EnrollingInfo
102060A Phase 1 Trial of SGN-CD70A in Patients with CD70-Positive MalignanciesActive/EnrollingInfo
102058A Phase Ib Dose Escalation/Randomized Phase II, Multicenter, Open-Label Study Of BYL719 In Combination With Cetuximab In Patients With Recurrent Or Metastatic Head and Neck Squamous Cell CarcinomaActive/EnrollingInfo
102050The Importance of Sinus CT in the Management of Neutropenic Fever in Children With Malignancies or Fever in Children Within One Year of Hematopoiectic Stem Cell TransplantationActive/EnrollingInfo
102049A Pilot Study Evaluating Racial Disparity, Environmental Toxin Exposure and Regulation of Anti-Inflammatory Mediators as Risk Factors for Endometrial CarcinogenesisActive/EnrollingInfo